Dr. Daniel Wallerstorfer
CEO and Founder of Novogenia

Dr. Daniel Wallerstorfer, an Austrian molecular biologist and biotechnologist, is the founder and CEO of Novogenia GmbH. With over 10 years of experience in the field, he has established himself as one of the leading experts in nutrigenetics and lifestyle genetics. Under his leadership, Novogenia developed innovative products in genetic testing, personalized dietary supplements, and cosmetic technologies. The company also played a significant role in the COVID-19 pandemic, establishing itself as a leading laboratory for SARS-COV-2 testing in Austria. With a strong focus on research, development, and innovation, Dr. Wallerstorfer has led not only Novogenia but also its parent company DARWIN AG, to new heights. Through his public presence as a speaker and author, he also promotes public understanding of the immense potential of human genetics in healthcare. 

MicrosoftTeams-image (9) (1)

The Scientific Contribution of Dr. Daniel Wallerstorfer: 


Daniel was the main driver for the following technical innovations at NOVOGENIA: 


Support for International Businesses 

Dr. Wallerstorfer has long established himself as a leading expert in his field. Numerous companies rely on his expertise in genetics, lifestyle genetics, and nutrigenetics. Furthermore, he regularly delivers lectures, sharing his extensive knowledge in the field of genetics. 

Among the companies Dr. Wallerstorfer works with include 


Dr. Daniel Wallerstorfer, born in Austria, is a biotechnologist and molecular biologist who completed a significant part of his higher education in the United Kingdom. He spent his first 14 years in Salzburg before moving to England to attend Ardingly College, located about 50 kilometers south of London. There, he successfully completed his A-Level examinations, laying the groundwork for his academic career in biotechnology. His scientific career took a decisive turn with his studies in Molecular Biology at the University of Manchester, one of Europe’s leading universities in the field of biotechnology.  

 The university is known for its intensive research and practice-oriented teaching, providing Dr. Wallerstorfer with a solid foundation for his later scientific work. After completing his Bachelor of Science (B.Sc.), he further specialized and pursued a doctoral degree in Biotechnology at the same university. In his doctoral studies, Dr. Wallerstorfer focused on optimizing expression systems for recombinant proteins, particularly in the medical context. His emphasis was on RNAi (RNA interference) and epigenetic processes in cells, research that is particularly relevant for developing innovative medical therapies and diagnostic methods.  

At the age of just 25, he was awarded the Doctor of Philosophy (PhD) degree by the University of Manchester. 

During his studies, Dr. Wallerstorfer developed a profound interest in human genetics, particularly in the possibilities of preventive genetic diagnostics. This early fascination laid the foundation for his professional career and led him on the successful path he follows today. He is not only an expert in his field but also a lifelong learner, constantly striving to push the boundaries of knowledge in molecular biology and biotechnology.